[HTML][HTML] Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection
MC Panelli, ME Stashower, HB Slade, K Smith… - Genome biology, 2007 - Springer
Abstract Background Imiquimod is a Toll-like receptor-7 agonist capable of inducing
complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …
complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …
Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.
MC Panelli, ME Stashower, HB Slade, K Smith… - Genome …, 2007 - europepmc.org
Background Imiquimod is a Toll-like receptor-7 agonist capable of inducing complete
clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …
clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …
Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection
MC Panelli, ME Stashower, HB Slade, K Smith… - 2007 - pubmed.ncbi.nlm.nih.gov
Background Imiquimod is a Toll-like receptor-7 agonist capable of inducing complete
clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …
clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …
[HTML][HTML] Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection
MC Panelli, ME Stashower, HB Slade, K Smith… - Genome …, 2007 - ncbi.nlm.nih.gov
Background Imiquimod is a Toll-like receptor-7 agonist capable of inducing complete
clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …
clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …
Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection
MC Panelli, ME Stashower, HB Slade, K Smith… - Genome …, 2007 - go.gale.com
Background Imiquimod is a Toll-like receptor-7 agonist capable of inducing complete
clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …
clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …
Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection
MC Panelli, ME Stashower, HB Slade, K Smith… - GENOME …, 2007 - air.unimi.it
BACKGROUND: Imiquimod is a Toll-like receptor-7 agonist capable of inducing complete
clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …
clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …
[PDF][PDF] Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection
MC Panelli, ME Stashower, HB Slade, K Smith… - Genome …, 2007 - researchgate.net
Abstract Background: Imiquimod is a Toll-like receptor-7 agonist capable of inducing
complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …
complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …
[PDF][PDF] Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection
MC Panelli, ME Stashower, HB Slade, K Smith… - Genome Biology, 2007 - Citeseer
Abstract Background: Imiquimod is a Toll-like receptor-7 agonist capable of inducing
complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …
complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …
[HTML][HTML] Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection
MC Panelli, ME Stashower… - Genome …, 2007 - genomebiology.biomedcentral.com
Imiquimod is a Toll-like receptor-7 agonist capable of inducing complete clearance of basal
cell carcinoma (BCC) and other cutaneous malignancies. We hypothesized that the …
cell carcinoma (BCC) and other cutaneous malignancies. We hypothesized that the …